Ever heard the story about someone who became mega rich overnight by buying a pharma stock…just before a new drug was approved?
Do you ever sit around and think, "I read a ton of information… I do a lot of stock research…so why haven't I hit my own pharma home run yet?"
Sometimes that just doesn't seem fair, does it?
You and I know that those people who got rich off of a pharma stock are not smarter than you. They've just been lucky enough to have access to "inside" information…
Well, today you have your own chance to get the "inside" information you need to win the FDA game…
You see, our friends over at Stansberry & Associates Investment Research just came across a penny stock pharma company that could land you some serious cash when the FDA announces results on their latest drug.
As soon as I read this report, I couldn't wait to share it with you.
If growing rich overnight on the next pharma breakthrough sounds appealing, just continue reading for all of the details…
We've waited 2 years for this day.
On March 30th, there'll be an announcement of FDA results for a new drug that could create the single biggest return of any investment we've ever found, in 10 years.
"All eyes are on the data," says Business Week. "It could be a multi-billion dollar drug, and so far, all the numbers have been positive." BioWorld writes: "It could be the largest pharmaceutical market ever."
When you see (below) what the drug treats... I think you'll see why S&A has now spent over $200,000 since 2006, uncovering the full details.
"It's the perfect storm," writes drug expert Jack Windin. "A totally new chemical entity with virtually no competition."
So far � the drug has successfully cleared both Phase 1 and 2 FDA clinical trials... and is just weeks from the announcement of Phase 3 results... the last trial before it could launch on a scale potentially unseen since the release of penicillin.
As Forbes reports: People across America are already writing letters to the small company who owns the patent... asking: "How can I get your drug?"
But the big question, of course, is: "Will the drug be approved by the FDA?"
By March 30 � we'll hear the official announcement of test results. It's a decision we've been following daily since trials first began more than 2 years ago.
And while most people have no idea what will happen... we've been able to access early results directly from the company, and they're even better than we hoped.
In short: as of Dec. 15, 2008, early clinical results suggest the drug is safe... has a near-perfect success rate... has a 500% efficiency... and finally, get this: will target 45% of the U.S. population � almost 1 out of 2 Americans.
As one FDA expert puts it: "If results on March 30th turn out even half as good as we expect... this could be the best-selling drug in the history of medicine."
Best of all: All the rights to the drug belong to a single company, a penny stock. At today's prices... a 4-point jump alone would double your money.
In other words: if the results are positive for this new drug on March 30th as we expect... a single stake in this company could make you a fortune, overnight. We estimate as much as $195,600... but only if you get in right now (you'll see why below).
Again, we've waited 2 years for this day. It's the kind of situation we built our firm on back in 1999... investments that can literally change your life.
Let me give you the full story...
Forbes: "The magic pill"
Years from now � and perhaps for the rest of their lives � a small group of people will remember exactly what they were doing on March 30, 2009.
You see, by that morning, there will be an announcement that's unlike just about any other FDA-related release. It's the single announcement that allows regular investors like you and me the rare chance to make a small fortune...
When Celgene (CELG) heard a similar announcement in 1998, for example, the best stock returned 1,002%... turning every $5,000 into $50,100 profit. (We're expecting an even bigger return this March.)
The same thing happened in 1991 to Amgen (AMGN) � which immediately doubled... and went on to gain an unbelievable 1,700%.
In short � by March 30th... we're expecting an announcement of something more than just new drug approval...
Quite simply, we expect approval for a new drug unlike anything to ever go public in the 81-year history of modern biotech. It's a drug that simply hasn't existed, in any useable form... until the company I'm telling you about invented it.
And yet it offers the one cure that almost everybody wishes for � at some point in life. (Don't worry, I'm not talking about something farfetched, like a cancer cure... or a fountain of youth.)
In fact, chances are you know someone who could benefit from the drug, and will even prescribe to it... after test results come out by March 30th.
The drug could help so many people a neuroscience writer in Dallas went as far as to say recently, "The FDA should lower requirements and speed up approval."
It's been described by even conservative health writers with words like: "runaway bestseller"... "blockbuster potential"... and "sell like gangbusters." Forbes wrote of the "magic pill," and went on to say:
"If approved, it could be a billion-dollar drug."
To put that in perspective: If the penny stock company that owns this drug makes even half that amount in revenue... the share price could rise by almost 1,000%.
Now you can see why all of us here at S&A are waiting for March 30th.
You see, only less than 1% of new drugs ever make it past the laboratory door... and through the FDA... for release to the American public.
But this situation is even rarer.
Simply put: not only do early test results suggest the FDA will grant its approval... but in addition � the drug would create an entirely new market, the likes of which no biotech firm... anywhere... has ever successfully tapped.
Let me explain...
Last untapped drug market
Last month, on January 11th, Brian Jennings of NBC Nightly News ran a top-of-the-hour story on a growing epidemic sweeping America...
According to the Centers for Disease Control and Prevention, it's already begun to affect two-thirds of the U.S. population � whether folks realize it or not.
Even more startling is the World Health Organization report: 1 out of 6 people worldwide are now affected by the medical problem being successfully treated by the drug I'm telling you about. That's ONE BILLION PEOPLE.
The problem has grown into such a major health concern MarketWatch reports that its treatment is now among the Top 10 Priorities of the U.S. Government.
And yet... there's no single drug available to treat it.
Big Pharma is pouring tens of millions into the effort. Many speculate a drug that successfully treats this problem (which I'll reveal below) would be, "the last of the traditional blockbusters... drugs that weigh in over $1 billion annually."
One drug expert calls the market the "biggest untapped goldmine in the industry" and speculates that it would be worth $10 billion per year.
That's why shares of the little drug developer I've been telling you about could go through the roof on March 30th, on the announcement of Phase 3 test results.
The reason: They have the #1 leading drug in development right now to treat this problem... and they're the only one of its kind right now to have completed both Phase 1 and 2 trials... and potentially tap the largest pharmaceutical market ever.
But the most important reason why this penny stock could jump so quickly come March 30th boils down to just one thing:
The drug works.
In a move quite rare in drug trials... many of the actual patients who are currently enrolled in tests are breaking doctors' orders to speak out in public.
"It's working great," says one patient � a 35-year-old woman. "I can't wait for it to come out. I feel it has been a great thing for me," says a 64-year-old man.
In December 2008, our top medical analyst uncovered early test results directly from the company.
And look at this: Last July � one of the biggest critics of the drug, Sandy Karle, an expert in the field (which I'll reveal below), wrote: "Forget it!" warning that it may not be possible to ever successfully treat this problem with drugs.But days later... after learning more, she publicly said:
"I am tempted to buy the stock. [This tiny company] will make a mint, and so will its investors. If you're looking to make money... it's a good choice."
So what does this drug cure, exactly? And why do experts think it could tap one of the last billion-dollar-drug markets in pharmaceutics?
Near 100% success rate
In short � the drug treats obesity.
With just a single pill... it lowers the patient's weight by at least 5% (the golden number in weight loss). If a patient can lose 5% of fat � academic studies have shown that this significantly lowers blood pressure... risk of heart disease, and other harmful effects like diabetes... arthritis... and stroke.
Even more amazing � unlike almost every other weight-loss alternative, the drug works without a single ounce of effort from the patient.
In other words: It requires no exercise... no special diet... and no risky operations in the hospital. You simply swallow the pill on a full or an empty stomach.
As one patient in the Phase 3 trial recently said, "I've lost 21 pounds (10% of my body weight) in 10 weeks. I couldn't be happier. I'm excited, because I wouldn't mind being able to wear a single digit size by next summer!"
"I have lost about 90 pounds," another patient said last month.
And a third Phase 3 patient recently said, "I lost 20 lbs (I weighed 160), my blood pressure went down, my cholesterol went down, all my levels are great now."
As I'll explain � the drug works by targeting a little-known part of the brain. (The British scientist who helped invent it detailed the entire process to us in his office.)
Specifically � it targets the brain area that controls the patient's appetite. When a patient takes the drug twice a day, it suppresses his appetite and he finds himself naturally eating less and less...
That's why folks struggling with their weight are so excited. It doesn't require any difficult program or diet � like the Jenny Craig work-out routines... or the untasty meals of NutriSystem or WeightWatchers.
When you prescribe to this new drug, you eat what you want, as often as you like. It's that simple. For folks who want to lose weight without sweating or sacrificing, it's about as good as it gets.
And as I said before � there's no other single drug on the market that offers it any real competition whatsoever. As Forbes recently wrote � the only two alternatives on the drug market deliver "mediocre results."
This drug, on the other hand, uses an entirely new molecular compound that has been patented by the company behind it... a compound so unique that practicing physicians nationwide are already taking notice...
At a recent meeting of the American Diabetes Association, for example, Dr. Steve Sarton, M.D., of the Biomedical Research Center devoted his talk to it, saying:
"The drug demonstrated excellent weight loss in this study � coupled with excellent tolerability and a positive impact on associated physical measures in obese patients."
In other words: The drug works.
But before I show you how it works... (and why we believe that even a small stake could make you as much as $195,600, overnight)... let me make something clear:
May not be right for you
Unless you're willing to act on this situation immediately � long before March 30th, when FDA results are announced � this investment may not be right for you...
You see � the big money in new drug development comes weeks... often months... in advance of FDA approval. And unless you act quickly, you miss out...
Take Oncogenex (OGXI), for example. A lung cancer drug they developed, OGX-011, hasn't even entered Phase 3 trials... and yet the stock is already up 1,728%.
Or look at Medivation (MDVN). Their new drug for Alzheimer's, Dimebon, is still in Phase 2 trials. But the stock is up 1,756%.
The point is � most people have never even heard of the little company who made the drug I'm telling you about... which is one reason it's still a penny stock.
But it's only a matter of weeks � even days � before this changes...
An almost identical situation recently played out with Auxilium (AUXL)... an East Coast drugmaker. Nobody had ever heard of this company when it began Phase 2 trials for a new testosterone drug...
But on October 26, 2005 � before results were even public... the executives held a press conference at The Palace Hotel in New York, to talk about it.
Just 5 DAYS LATER... on Oct. 31... the stock began a 973% run.
And unless you'd gotten in before the press found out... you'd have totally missed out on this situation. By waiting, you'd have missed a near-10 BAGGER.
Well � this opportunity is even bigger. And the reality is: The top stocks could start its run any day now. The company issued 3 press releases in December alone. We're expecting an even bigger press release about the drug literally at any minute.
But whether you follow our advice... or wait until the last second, there's only one thing you need to know about this drug to make a fortune...
Secret of top 100 drugs
You see � the top 100 bestselling drugs in history all have one thing in common... as do 50% of all successfully launched drugs of the past 30 years...
In short, they're all compounds that target proteins in the human body known as the "G-protein-coupled receptors" (or "G-proteins" for short). Most people have never heard of it, but this secret little protein has produced over $30 billion in sales on the drug market.
Well... the drug I'm telling you about also targets "G proteins."
But unlike 99% of the market, it does something no other biotech firm, anywhere, in the history of pharmaceutics, has ever safely accomplished...
Quite simply: It targets "G proteins" in the brain, activating a single very tiny portion that controls appetite... the feeling of being "full" after eating.
This part of the brain is known as the "hypothalamus," and is filled with the same chemical that controls sex... and sleep. But what makes the drug so unique is that it can isolate and activate the "appetite" part alone... with 100-FOLD selectivity over the other 2 parts... the only drug to have ever done this.
Targeting G-proteins � the drug literally enters your brain... and sends out a chemical message saying, in effect: "You're full. There's no need to eat any more."
As I said before... the top 100 bestselling drugs in history
have used the G-protein secret in a similar way � but never, ever, to treat obesity. What this means for you, as an investor, is just one thing. Take a look...
Here are 4 examples of other "G-protein" drugs... and how much they made after receiving FDA approval and launching worldwide...
The best part: If the penny stock behind this new obesity drug were to make only a fraction of those numbers � say $250 million � the stock could triple.
If it made $500 million in sales... it could rise 978%. And if it made one billion in sales... the price could rise 1,956%. That turns every $10,000 stake into an unbelievable $195,600 profit.
Now you can see why BusinessWeek says, "All eyes are on the data" and why S&A has spent over $200,000 since 2006 uncovering the full details...
And that's not all...
A 229%, 1-day perk
There's an extra perk to this opportunity, which could make you another 229%... in the space of just 8 hours or less...
Now bear in mind: The real money you should expect to make from this drug will come as a result of March 30 � when the Phase 3 test results are announced.
But there's a good chance that before this happens... this tiny company will accept a lucrative licensing offer from a larger biotech firm. In fact � when we spoke to the firm's CEO at their headquarters, he said he's already on the lookout for a deal...
The windfall could be enormous. Take SGX Pharma (SGXP), for example... When they accepted a licensing offer from Eli Lilly on July 8, 2008, they saw a 125% 1-day jump in share price.
Kosan Biosciences (KOSN) made a 229% 1-day jump after a licensing offer from Bristol-Myers (BMY) on May 28, 2008.
And Barrier Therapeutics saw a 128% 1-day jump on June 24 of last year after a licensing offer from privately-held Stiefel Labs.
Again: this is only an added perk. We expect the real gains in share price to arrive as a result of March 30th � the day we've been awaiting for 2 years...
But given the company's history, there's a high probability a licensing deal could happen any day now... as early as next week... or even tomorrow morning.
You see � this tiny drugmaker has already used its "G-protein" approach to make two other brand-new drugs, which have both been licensed, by the biotech giants Johnson & Johnson... and Merck (multibillion-dollar heavyweights).
**The Merck deal is for the company's heart drug... which began a Phase 2 trial recently that triggered a $4 million payment to the firm, with another $32 million in potential royalties.
**The Johnson & Johnson deal is for the company's diabetes drug... worth $295 million in future royalties.
In short... there's a good chance this company will strike another deal with a giant firm (with a greater marketing budget), to license the drug I'm telling you about... especially given that the obesity market is being called "an untapped goldmine."
And if that happens, you could see an extra 229% 1-day jump in share price, more than doubling your money if you own shares before the announcement...
Coffee with the CEO
But before I give you the specifics on how to play this stock, you should know that our analysis comes from a single source we've been using since 2002...
It's easily S&A's #1 biotech secret � and has already pointed to some of the fastest and biggest gains we've found in this sector since our firm first began...
Like Crucell (CRXL), for example, a vaccine maker that shot up 1,145% since we first told readers about it. Or Sirna (RNAI)... which was bought out by Merck after we found it and doubled overnight, a 201% gain.
In short, I'm referring to Rob Fannon.
Unlike most of our analysts... Rob doesn't get his information through traditional means. He doesn't sit behind a laptop all day, reading financial reports... or trying to cold-call company executives for a hot tip...
Quite simply � Rob uses his personal connections in the academic and the private sectors of medicine, obtaining data most people never see until it's too late...
For example, Rob was the first to tell us about Esperion... a firm that developed a radical new way to treat heart disease. By chance, he worked down the hall in Los Angeles' Cedars-Sinai Hospital and Research Center from one of their top clinical researchers � Dr. P.K. Shah, a man who's been profiled by USA Today.
By getting to know him, Rob learned that Esperion's Phase II test results showed their drug could successfully remove arterial plaque � reversing heart disease.
Rob immediately gave us the full details... and 3 WEEKS LATER, Rob's readers saw 55% gains OVERNIGHT, when the company was sold to Pfizer.
For the drug I've been telling you about � Rob has been using his connections for the past 2 years, ever since he first learned about it in 2006 from the CEO.
Since then... we've allowed Rob a budget of almost a quarter million dollars to learn more. That may sound like a lot of money... but it's been more than worth it. Take a look:
Rob flew out to the company headquarters... toured their private facility... and met over coffee with the CEO, to find out exactly when the drug will be ready. He then met the drug's British inventor, joining him in his office... a room lined with academic tomes and medical journals.
Later Rob called a Ph.D. gastroendocrinology expert at Johns Hopkins University... and then held a conference call with both his Hopkins Ph.D. contact and the company's CEO, to discuss even further.
In short, Rob probably knows more about this new drug than any other analyst in America. He's really the only person you should follow to profit from it...
You see, when it comes to making money in biotech... you have to understand the science... you have to understand the business. And you have to develop contacts. All this costs tens of thousands of dollars and many years to accomplish...
That's why Rob's full report on this drug � March 30: Biotech's Last Great Blockbuster � (details below) will show you exactly how to get in right away... for the biggest return in the shortest amount of time.
But is this investment right for you?
Well... whether you put your money in this penny stock or not, all I can say is that when it comes to finding little biotech firms that can make people a fortune... I've never met anyone with better inside access than Rob Fannon...
Long before we ever hired Rob, for example, he analyzed Intuitive Surgical (ISRG) for us, a surgical device maker. It rose 133%.
Same thing with Elan (ELN), a drugmaker for immune disorders. Rob was among our consultants... and the hot stocks skyrocketed over 400%.
But there's another reason why Rob's research can make you rich...
Early stage windfalls
Passing him on the street, you'd probably never even notice Rob Fannon...
A quiet man, he spends his days in a small office peering through his pair of dark-framed glasses at medical journals (The New England Journal of Medicine), and pausing to look out the window at the Baltimore skyline.
But throughout his career, Rob has uncovered a proven way to make the quickest, biggest gains on no-name biotech stocks, a strategy for uncovering the best early- stage windfalls in the business (like the overnight double on RNAI).
In a nutshell: he's a Phase 1 trial expert.
A Phase 1 trial, as you probably know, is the first step in FDA clinical trials before a company can receive approval for a new drug or medical treatment.
The most profitable "Phase 1" developments are those made by small, early-stage companies with BIG IDEAS that can change the face of medicine... with potential to grow 1,000% or more... like the one I've been telling you about in this letter.
I've been in the financial business for almost a decade, and even now � after everything I've seen � nothing compares to the feeling of watching a tiny stock take off, turning a small stake into a bigger sum of cash than you've ever made on a single investment.
It's how I felt when we recommended JDS Uniphase, for example � which gained 592%... Texas Instruments (301% gains)... Cree (271% gains)... and Seabridge (700%+)... among many others.
These are the situations Rob specializes in... Put simply: To really make money with drugmakers... you absolutely MUST know the scientists... researchers... doctors... FDA officials and CEOs who understand � long before Wall Street � where the next "big thing" is coming from.
Experts in every industry always know more than outsiders, but when it comes to FDA test results like those we're anticipating on March 30th... where approval can make or break a company... "on the ground" perspective is critical.
Frankly: these are the kinds of investment opportunities that can literally change your life... where an investment of $10,000 can quickly turn into enough to buy a beach house... or pay for several kids' college education... or allow you to just quit your job � forever � and retire on the proceeds.
It happens a lot more than most people think � you just have to know about the RIGHT company at the RIGHT time... with help from the experts directly involved.
Now you can see why Rob has gone through a $200,000 budget to research the company I'm telling you about...
Again: this penny stock has already put the drug through its PHASE 3 trial, which will have its results announced by March 30th.
And it gets even better...
Not only has Rob prepared a detailed Research Report giving you the full story of this company... and how to get in for the biggest possible gain... but:
Rob has also found a secret way to eliminate much of the risk in the best stock, while giving you an even FASTER way to see a triple-digit upside.
Let me explain...
Shortcut: 400% upside
There are 2 ways to play this opportunity.
The first is by simply buying shares of the penny stock, which Rob outlines in his full report.
But there's a second play that you can use to get into the stock... and as a result � reduce your risk to almost nothing while shortcutting to 400% in possible returns. We've done this many times before at S&A Research...
For example: last July we did this with healthcare firm Palomar Medical (PMTI)... and saw 490% gains on just a tiny move in the stock.
Or consider March 2007. The FDA announced test results for a new drug by Dendreon (DNDN)... and S&A readers saw a 314% jump in the stock. But by following our 2nd play � some made even more...
Joe Samuels from Woodland, Calif. saw a 1,017% return in less than 48 hours... enough to turn every $5,000 stake into $50,850. And John Bailey saw a 771% return from the FDA announcement.
In short � Rob is also recommending an options play.
You see, with options, you can make 10 TIMES the return of a stock... often even more. All it takes is just a tiny move in share price to make you a killing.
For example, in early December we published an options play for Silver Wheaton (SLW), a silver miner. The stock barely moved, inching up 3 points... But readers saw a 250% gain � in just 14 DAYS.
That's the great thing about options: Not only can you make more money, but the return comes FAST... in many cases, on the exact same day you get in:
That's why in Rob's full report about this situation, he'll be including details on a secret options play � a way to ensure that even the tiniest move in the stock could shoot your return many times higher, immediately, to at least 400%.
But I know what you're thinking: "Options are risky..."
Well, the truth is � by using options you can actually REDUCE your risk. It's simply a matter of poring through dozens of potential plays, looking for the perfect option. And in biotech, that requires days of analysis by only a veteran trader.
Fortunately for Rob... he's got a secret weapon in the options business.
Meet Dr. George Huang � a Ph.D. biochemistry expert who specializes in options biotech plays, with a focus on companies on the verge of major buyouts:
When Indevus Pharm. (IDEV) got bought out by Endo (ENDO) in early January... Dr. Huang's options play saw a 186% 1-day gain.
Dr. Huang's play for Neurocrine Biosciences (NBIX) saw an astonishing 100% gain in just 14 days. His play on ImClone... 100% in 30 days. And Alpharma.: 100% in 58 days.
Quite simply: With additional analysis from Dr. Huang, Rob has pinpointed what we believe is the single most effective and safest options play for this situation.
In Rob's new report � March 30: Biotech's Last Great Blockbuster � he'll explain exactly how to execute the play... for the biggest gain in the shortest time span.
If you'd like to get a copy... well, I have some bad news.
As I warned you earlier, this investment opportunity won't be right for you unless you're willing to execute Rob's recommendation immediately.
But there's another reason why this situation may not be right for you... especially in today's markets and economy. So I urge you to read on carefully.
Be aware of 3 things:
To put it gently: Unless you can afford it... Rob's research is probably not the best thing for you right now. And in fact � it probably never will be...
You see � unless you're one of the more experienced readers: You simply don't have the resources to 1) pay full price for this work (see below)... and 2) take a large enough stake in the play for a chance at making real money.
But more importantly...
3) Unless you're comfortable making very speculative plays in top stocks, which most people have never heard of, or unless you just want to watch and learn � you'll be wasting your time.
Said differently: The investment opportunities Rob uncovers aren't for ordinary investors: Folks who wait around for dividends and rely on 401(k)s. It isn't meant for amateurs trying to get a hot tip to pad their Social Security income...
If that sounds like you, please stop reading now.
In short, we only publish Rob's research for a very small audience: folks who have the resources to afford it... cash in on it... and might want to stomach the often bumpy ride of biotech � which most people try to avoid.
And that's why we're limiting access to Rob's new Research Report (March 30) to our most expensive and sophisticated advisory service: Phase 1 Investor.
To my knowledge � there's no other investment research service in the world that compares to Phase 1 Investor. It costs more to produce than any other advisory at S&A Research... not just in terms of
money, but in sheer time alone.
Tracking down tiny companies with early-stage breakthroughs takes months and sometimes years
of research. (As I said before: we've waited 2 years for test results on the drug I've been telling you about.)
Tens of thousands of dollars go into each new recommendation, on travel (air and hotels)... consultant fees... lab tests (on occasion)... and conference meetings.
To keep up with modern biotech, every month, Rob logs hundreds of air miles, to attend meetings for The American Society of Hematology... The American Society of Clinical Oncology... The Drug Information Association... and many other major meetings of the world's top medical specialists.
In other words: Phase 1 Investor is where we publish our most rigorous research.
As a matter of fact: That's one reason we hired Rob. Most analysts hate doing the legwork of research, but there's nothing Rob loves more than flying around the country to meet with executives and key personnel behind Phase 1 trials. (It's not surprising, given his background...)
You see � Rob studied physiology and biochemistry as an undergraduate, and has worked as a scientist in both the academic setting and the private sector.
He got his first big break from the Government's top medical headquarters... The National Institutes of Health (NIH)... where the country's best scientists evaluate new drugs and medical breakthroughs, and award billions in grants.
In particular, he did NIH genetics work for a Maryland-based biotech company... which he helped expand, by setting up a new division in Hyderabad, India.
At Johns Hopkins University, the country's top medical school... he got a Masters degree in Public Health, an MBA, and made several key contacts.
He also worked at Cedars Sinai Medical Center, in the prestigious Comprehensive Prostate Cancer Research Program, where he made other contacts (such as Dr. P. K. Shah, who tipped him off to Esperion � which gained 203%.)
Bottom-line: Rob is uniquely qualified in this business.
In fact, when Rob finished school... at first we didn't think he would come to work for us... especially after what he said during his interview:
"I don't want to write any advertisements," he told us right away. "I don't like any hype."
You see: Rob has never been comfortable with financial advertising � which of course portrays every single investment idea as the Holy Grail of Biotech... the cure of cancer... and so on.
In fact, for many months in the beginning... he didn't allow us to advertise Phase 1 Investor at all. Unless you knew about it, there was no real way to get in.
But that's what I love most about Rob: He's conservative. He's quiet. He's safe. I'll give you a quick example... so you can see how important this is in biotech.
A while back... Rob found a tiny biotech company called Renovis (RNVS) that had just developed a new drug for stroke victims.
From a medical standpoint, Rob found the drug � and the company behind it � compelling... so he immediately paid a visit to his friend and colleague, the head of Johns Hopkins University Stroke Research.
Right away � his Hopkins contact said: "No way. You're flipping a coin on this."
Rob scrapped the idea. 3 months later, Renovis TANKED 75% when the Phase III trial failed. Rob avoided this bomb as a result of good, hard diligence.
Bottom-line: When Rob makes a recommendation... you can be sure he's studied it from every angle, to make absolutely sure that you're going to make money.
Walking past his office recently, I saw him hunched over his computer, typing up his new report (March 30)... long after most of our employees had gone home for the day. I knew he'd be there for hours.
But that's exactly what you want when it comes to investing in new drugs: a smart analyst who lives for these situations, interviewing the key insiders who know.
The only question is: Assuming you can afford Rob's research (see below for what we're asking), is this new obesity drug truly the right investment for you?
CEO will brief you
I recommend you decide for yourself after learning the full details from this tiny company's CEO... who will brief you on how it works.
You see, as part of his research � Rob held a conference call with Phase 1 readers and invited the CEO, along with a weight-loss expert at Johns Hopkins... and the full transcript of the call is available online, for all new Phase 1 members.
When you join Phase 1 Investor... you'll receive instant access to the transcript along with Rob's full new report: March 30: Biotech's Last Great Blockbuster.
This isn't a one-time thing, either. Every month, Rob puts together an extremely detailed Research Report on a new Phase 1 opportunity. When appropriate, he'll then host a special Conference Call or Web conference to discuss the situation in full.
Joining Rob on these conferences will be industry insiders, company executives and independent researchers he meets while investigating each new opportunity.
(Of course, you'll be invited to join as well, so you can hear and learn about these new developments and great opportunities firsthand. If you can't make it... don't worry. Rob will always post the conference for you, online.)
**In fact, on February 11th, Rob will be hosting a new conference to discuss this opportunity... featuring biochemical options expert Dr. George Huang, along with Rob's contact at Johns Hopkins University, a professor of medicine who has been studying obesity for almost 20 years... has published 19 science articles about it... and has worked with the Government's NIH.
The conference will be online. Simply log on... and listen. You'll be able to submit any questions you might have � and hear the panel's response.
The only catch: You must reserve your spot immediately. (You can get started by following the link below.)
By reading Rob's full report... and listening to the experts firsthand... you'll know for sure whether or not the investment is right for you.
As you can see � we do everything we can to make sure the recommendations in Phase 1 Investor are among the best-performing research we publish.
As a matter of fact � several CEOs of the companies Rob has recommended have told him his research is the most informed of any analyst they've seen.
And that's why Phase 1 Investor is our most expensive research service.
That said, I believe Phase 1 Investor is actually also the best bargain of anything we publish � considering the amount of time... money... and effort that goes into each new recommendation.
The cost for one full year of Phase 1 Investor is $5,000.
If that sounds like too much money, I can tell you right now: Rob's report won't be right for you. I suggest you look into one of our other research advisories, such as 12% Letter or True Wealth... for folks who are just starting out.
But there is some good news. For reasons I'll explain shortly � for a limited time only, you can get Phase 1 Investor for almost 50% off the standard price.
Quite simply, you can become a member for just $2,600.
Believe me � we don't do this often. Once the offer expires, the price will go right back to $5,000... and will probably stay there for quite some time.
But we're making you this offer because the truth is... we believe the coming year is going to trigger an absolutely incredible biotech bull market. In particular, Rob thinks we'll see a tidal wave of mergers and acquisitions... such as the one we just saw in early January � when Indevus got bought out by Endo. (Rob's readers saw a 1-day gain of as much as 186%. And that's just the beginning...)
You see � in the past four biotech bull markets, you could have booked 3 triple-digit gains and one quadruple-digit return... simply by buying the biotech index.
Imagine, on the other hand, banking several-hundred-percent gains on one small stock after another... like the
one Rob shares in his new report: March 30.
As I said earlier, that's why we publish Phase 1 Investor: to focus on the kinds of opportunities we simply can't recommend to a mainstream audience.
If this sounds like something you're interested in, here's what I recommend:
Sign up right now for a trial subscription to Rob Fannon's Phase 1 Investor. You'll have immediate access to Rob's full new report outlining the opportunity I've been telling you about: March 30: Biotech's Last Great Blockbuster.
Even better: You'll have access to Rob's full archive of Research Reports � where you'll learn about 17 more Phase 1 opportunities he still considers a strong buy.
And you'll also receive full details on how to attend the Web conference Rob will be hosting on February 11th, with his panel of biotech and obesity experts.
Then, take the next 3 months to decide if Phase 1 Investor is right for you.
During that time � you'll receive Rob's monthly reports... and be invited to join any special conference-call meetings.
And remember...
As I've said throughout this letter: We're all waiting for March 30, when the FDA results will be announced for a new drug that could soon become "the bestselling drug in the history of medicine," as one experts puts it... and successfully tap "the largest pharmaceutical market ever" (BioWorld). According to Rob, this is one of the most exciting events he's seen in his career. If you're even considering a stake in this company... I urge you: get your hands on Rob's report, immediately.
If you decide Phase 1 isn't for you, simply cancel your subscription before your 3-month trial period is up. You'll get a full refund � 100% � no questions asked.
Remember � your chance to save ALMOST 50% on a full year of Phase 1 Investor will end shortly. After that... this offer expires.
P.P.S. As I mentioned earlier, we believe the announcement on March 30 could create the single biggest gain of any investment we've ever found... in 10 years in the business. But I'm sure you have a few questions about this situation, and I imagine you have a few doubts I haven't covered here.
That's why we've prepared a special "Frequently Asked Questions" section of this letter... which you'll find below, telling you exactly what we know... how we know it... what to expect... and why the biggest potential return could come any day now.
Frequently asked questions:
Q: How can I be sure results will come out on March 30th?
A: Rob Fannon has received a 141-page official document about the drug directly from the company headquarters. On page 12 � it says explicitly that at the end of March, results will be announced.
Q: What if the drug doesn't receive approval?
"I have lost about 90 lbs., can actually exercise, and I can look in the mirror without flinching. Of particular note was the fact that I cannot stand to eat chocolate or fried foods. They both make me nauseated. Quite a change from the dark chocolate gobbling junkie I was prior to the program."
- 45-year-old man in drug trial
"I'm just completing my first week in the study. But as a diabetic, I'm thrilled to say my blood sugar's nearly down to normal from sky high a week ago. I definitely find my appetite's greatly reduced and I have to structure my eating to ensure I don't forget meals."
- 37-year-old woman in drug trial
A: We already know the drug works. We have quotes from patients (see right)... and we have early results from the Phase 3 trial, showing that it beats the placebo (no drug) by 500%... and has successfully treated
almost every single one of those on drug among the 3,000 patients currently enrolled in the clinical trials.
And don't forget: Unlike most new drugs, this one has already cleared the Phase 1 and the Phase 2 trials. In other words: all that's left is the red tape of filing it with the FDA. That's why most new drugs (like the examples I gave earlier) usually see their biggest returns long before the FDA gives official approval.
Having said that � yes, there is always the possibility of this drug not receiving approval. But this is the type of speculation that's definitely worth taking in the investment world... where the odds are extremely high in our favor... along with the very real potential to risk a small amount of capital � and see gains of 400% or more. Of course � you should not get involved if you cannot accept that risk. And even if you can, we recommend you invest only a tiny fraction of your overall portfolio.
Q: What if the results aren't as good as you hope?
A: We believe it won't matter. As you know, the markets rise and fall on emotion more than anything else. Even if results aren't totally perfect � it could attract so much heated attention the drug will appear in newspapers... magazines... and on news shows.
And as I pointed out earlier... once the press catches on to a situation like this, it's all over. The best stock has usually taken off. That's why it's critical to get in before the media hype begins.
Q: What makes you so sure the media will jump all over this event?
A: Well, even as I was writing this letter... we saw 2 separate reports on the NBC Nightly News show about the growing problem of obesity in America. In fact, one story told of how the U.S. Army is taking steps to reduce obesity.
Not a day goes by in this country when there isn't some new study or news report detailing the negative effects of obesity. The bottom-line is: The number of overweight people in America is attracting the notice of medical professionals everywhere, and even the Government.
If this drug goes public � it could be given to so many people, old and young, man and woman, that it would become a household name... create a market worth $10 billion... and turn early investors into millionaires. It's that simple.
Q: What if I decide this investment isn't right for me?
A: No problem. You'll receive 3 full months to give Rob's Phase 1 Investor a no-risk trial subscription. Once you read his report... and look through his archive... if you decide his work isn't right for you, just let us know.
You'll get a total refund � every last cent, no questions asked. And his new report, March 30: Biotech's Last Great Blockbuster, will be yours to keep.
Posts
No comments:
Post a Comment